Johnson & Johnson (NYSE:JNJ) Stake Raised by AMI Investment Management Inc.

AMI Investment Management Inc. lifted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 6.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 25,492 shares of the company’s stock after acquiring an additional 1,607 shares during the period. Johnson & Johnson accounts for about 1.2% of AMI Investment Management Inc.’s portfolio, making the stock its 27th biggest position. AMI Investment Management Inc.’s holdings in Johnson & Johnson were worth $3,687,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Providence Capital Advisors LLC raised its position in Johnson & Johnson by 12.4% in the second quarter. Providence Capital Advisors LLC now owns 40,909 shares of the company’s stock worth $5,979,000 after acquiring an additional 4,500 shares in the last quarter. Cheviot Value Management LLC raised its holdings in shares of Johnson & Johnson by 9.4% in the 2nd quarter. Cheviot Value Management LLC now owns 144,825 shares of the company’s stock worth $21,168,000 after purchasing an additional 12,488 shares in the last quarter. Marshall Wace LLP lifted its stake in Johnson & Johnson by 506.9% during the second quarter. Marshall Wace LLP now owns 3,884,962 shares of the company’s stock valued at $567,826,000 after purchasing an additional 3,244,862 shares during the last quarter. Distillate Capital Partners LLC acquired a new position in Johnson & Johnson in the second quarter worth approximately $50,013,000. Finally, Gateway Advisory LLC increased its holdings in shares of Johnson & Johnson by 240.0% in the second quarter. Gateway Advisory LLC now owns 16,780 shares of the company’s stock valued at $2,453,000 after buying an additional 11,844 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Up 0.7 %

Shares of Johnson & Johnson stock opened at $148.10 on Wednesday. The firm has a market cap of $356.57 billion, a price-to-earnings ratio of 21.43, a P/E/G ratio of 2.39 and a beta of 0.51. The stock has a 50-day simple moving average of $148.35 and a 200-day simple moving average of $156.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 71.78%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on JNJ shares. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, January 17th. Barclays cut their price objective on Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a report on Tuesday. Morgan Stanley raised their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Guggenheim boosted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Finally, Citigroup lowered their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $173.27.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.